Navigation Links
Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy

BETHESDA, Md., May 20, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chief Technical Officer, Dr. Marnix Bosch, will give a presentation on "Autologous Dendritic Cells for Glioblastoma" on Saturday, on May 21, at 1:45 pm at the 14th Annual Meeting of the American Society of Cell and Gene Therapy in Seattle, WA.  Dr. Bosch's talk will take place in rooms 615-617 at the Washington State Convention Center.


Dr. Bosch will provide an update on NWBT's DCVax® -L therapeutic cancer vaccine for Glioblastoma multiforme ("GBM"), the most lethal form of brain cancer.  DCVax® -L is in a Phase II, randomized, double blinded, placebo controlled clinical trial at multiple institutions.  The trial is designed and powered at a level comparable to a pivotal study.  Dr. Bosch's presentation will discuss the striking long-term follow-up data from prior trials, the design of this ongoing Phase II trial, and plans for further clinical development of DCVax®-L for brain cancer. The update will include discussion of the lack of toxicity, ease of administration, and other characteristics of the product and its clinical implementation that will make it suitable for widespread adoption in the medical community.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company is developing dendritic cell-based vaccines.  The Company's lead clinical trial is its 240-patient Phase II trial in newly diagnosed GBM.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.    

For further information about clinical sites and about the Company, please visit the Company's web site at


Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.    

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
2. Northwest Biotherapeutics Addresses Recent Market Activity
3. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
4. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
5. BioSpace Highlights the Northwests Growing Life Science Region
6. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
7. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
8. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
9. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
10. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... KONG, Nov. 23, 2015 China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended September 30, 2015. --> ... , Revenues for the second quarter of fiscal ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):